ClinicalTrials.gg
RecruitingNCT05523128Updated Feb 21, 2025

The Efficacy and Safety of ZS802 in Chinese Hemophilia A Patients.

An interventional study of ZS802 in Hemophilia A, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Recruiting at 1 site in China. Open to male participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-02-21.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started Sep 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Hemophilia A by Institute of Hematology & Blood Diseases Hospital, China — 11 open to participants now, 12 under way, none of them phase 3. Hemophilia A · Institute of Hematology & Blood Diseases Hospital, China.

Started
2022
with 1 other
No phase
3 of 13
3 open now
Primary completion
2025-10
later than 2 of 11 live
Registered
6th of 13
by date

Among the 13 studies in Hemophilia A by Institute of Hematology & Blood Diseases Hospital, China, this one is one of 2 that started in 2022, is one of 3 with no phase, reaches primary completion later than 2 of the 11 other live ones, and was the 6th registered.

Hemophilia A

845 studies on the registry are indexed under Hemophilia A; 137 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

11 of the 13 studies in Hemophilia A by Institute of Hematology & Blood Diseases Hospital, China are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 88 Hemophilia A studies recruiting now, 52 (59%) set no upper age limit and 31 (35%) stop at 75 or younger; 56 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 65 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Hemophilia A by Institute of Hematology & Blood Diseases Hospital, China, or all of them as a file.
02

Study summary

A non-randomized, open-label, dose-escalation study to evaluate the safety, tolerability, kinetics and efficacy of a single intravenous infusion of ZS802 in hemophilia A subjects with endogenous FVIII ≤2%.

Read the detailed description

This study will seek to determine the safety, tolerability, kinetics and efficacy of a single IV infusion of ZS802.

Hemophilia A is a genetic bleeding disorder resulting in the lack of ability to produce blood-clotting factor VIII (FVIII). Individuals with hemophilia A suffer repeated bleeding events, which can cause chronic joint disease and sometimes leads to death due to the inability for blood to clot efficiently. The current treatment is intravenous infusion of FVIII protein products, either prophylactically or in response to bleeding. ZS802 is an adeno-associated viral (AAV) vector designed to drive expression of the human factor VIII (hFVIII) transgene and raise circulating levels of endogenous FVIII.

6 patients will be enrolled sequentially every 3 weeks or more between cohorts and administered with single infusion of ZS802. Dose escalation may occur based on the safety and FVIII activity on steady state. The dose levels are as follows: 1. 2.0×10\^13vg/kg; 2. 6.0×10\^13vg/kg. Subjects will provide informed consent and then undergo screening assessments up to 6-8weeks prior administration of ZS802. All subjects will undergo 52 weeks safety and efficacy observation.

03

Conditions studied

  • Hemophilia A

Browse trials for

Keywords

  • Hemophilia A
  • Gene therapy
  • Adeno-associated virus
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male ≥18 years and ≤65years of age;
  2. Confirmed diagnosis of hemophilia A, and endogenous FVIII ≤2%:

    1. \<1% (\<1 IU/dL) endogenous FVIII activity levels as historically documented by a certified laboratory or screening data results; OR
    2. 1%-2% (1-2 IU/dL) endogenous FVIII activity levels and >10 bleeding events per year (in the last 52 weeks prior to screening); OR
    3. 1%-2% (1-2 IU/dL) endogenous FVIII activity levels and on prophylaxis;
  3. Have had ≥150 prior exposure days (EDs) to any recombinant and/or plasma-derived FVIII protein products.
  4. Agree to use reliable barrier and prohibition of sperm donation until 52 weeks after the administration of ZS802.
  5. Subjects voluntarily participate and are fully informed, fully understand the research and can comply with the requirements of the research protocol, are willing to complete the research as planned, and voluntarily cooperate with the provision of biological samples for testing.

Exclusion criteria

Exclusion Criteria:

  1. to any component of the study drug (including ) or a condition that can not use.
  2. Inability to tolerate immunosuppressants or drugs.
  3. Have no measurable FVIII inhibitor as assessed by laboratory; or documented no prior history of FVIII inhibitor.
  4. Who have a history or are currently suffering from any of the following serious clinical diseases:

    1. History of or current presence of any malignancy;
    2. Have active disease;
    3. Severe heart disease, including angina pectoris, myocardial infarction, heart failure, congenital heart disease, heart valve disease, arrhythmia and atrioventricular block, etc.;
    4. Have underlying liver disease or history of liver disease (such as portal hypertension, ascites, splenomegaly, esophageal varices, hepatic encephalopathy or hepatic fibrosis);
    5. Have active infection (HBsAg positive or HBV-DNA positive) or active infection (HCVAb positive), or are currently receiving hepatitis B or hepatitis C antiviral therapy;
    6. Have history of chronic infection or other chronic disease that the Investigator considers to constitute an unacceptable risk;
    7. Diabetes mellitus that is poorly controlled after drug treatment;
    8. Uncontrolled hypertension or hypotension;
  5. laboratory values:

    1. \<110g/L;
    2. \<100×10\^9/L;
    3. , ALT, alkaline phosphatase>2×;
    4. Total >1.5×ULN;
    5. Creatinine>ULN;
    6. Albumin\<LLN;
    7. antibody positive or Treponema pallidum antibody positive.
  6. Have AAV5 capsid neutralizing antibody titers >1:5.
  7. Those who have received clinical trials of gene therapy before screening, or have used FVIII clinical trial drugs within 1 month, or participated in other drug/device clinical trials within 3 months, or plan to participate in other clinical trials during this study.
  8. Those who have planned surgery within 52 weeks after the infusion.
  9. Those who donated or lost more than 400 mL of blood within 3 months before screening.
  10. Those with epilepsy, history of mental illness (such as schizophrenia, depression, mania or anxiety) or obvious mental disorder, incapacitated or incapacitated by other reasons.
  11. Patients with a history of drug abuse or alcoholism.
  12. Investigators believe that subjects have poor compliance or are expected to be less likely to complete follow-up.
  13. There are clinically significant diseases or other reasons that the researcher and/or collaborators consider unsuitable to participate in this researcher.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    ZS802

    Single intravenous (i.v.) infusion of ZS802 Intervention: Gene Therapy / Gene Transfer

    Genetic: ZS802

Interventions

  • GeneticZS802

    A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor VIII variant. The dose levels are as follows: 1. 2.0×10\^13vg/kg; 2. 6.0×10\^13vg/kg.

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    An adverse event (AE) is any medical occurrence, the event will not relate to the treatment.

    Time frame: Baseline up to Week 52

  2. Number of participants with clinically significant change from baseline in vital signs

    Vital signs will be obtained with participants in the seated position, after having sat calmly for at least 5 minutes. The clinical significance of vital signs will be determined at the investigator's discretion.

    Time frame: Baseline up to Week 52

  3. Number of participants with clinically significant change from baseline in physical examination findings

    Findings will be considered to be clinically significant based on the investigator's decision.

    Time frame: Baseline up to Week 52

  4. Number of participants with clinical laboratory abnormalities

    Findings were considered to be clinically significant based on the investigator's decision.

    Time frame: Baseline up to Week 52

Secondary outcomes

  1. Vector-derived FVIII:C Activity

    Peak and steady-state vector-derived circulating FVIII activity levels, and changes of FVIII activity levels after treatment compared with baseline.

    Time frame: Baseline up to Week 52

  2. Vector-derived FVIII antigen levels

    Peak and steady-state vector-derived circulating FVIII antigen levels, and changes of FVIII antigen levels after treatment compared with baseline.

    Time frame: Baseline up to Week 52

  3. Vector shedding of ZS802

    Blood, saliva, urine and semen will be collected to assess clearance of vector genomes.

    Time frame: Baseline up to Week 52

  4. Antibody against AAV capsid protein

    Immune response against AAV capsid will be evaluated by measurement of the binding antibody and neutralizing antibody against AAV capsid protein in plasma samples.

    Time frame: Baseline up to Week 52

Other outcomes

  1. Annualized bleeding rate changes from baseline

    The number of bleeding episodes per participant will be recorded, and the annualized number of bleeding episodes was calculated.

    Time frame: Baseline up to Week 52

  2. Annualized FVIII consumption changes from baseline

    The use of on-demand FVIII replacement therapy will be recorded by dose (IU/kg) administered, and the annualized use of FVIII replacement therapy will be calculated.

    Time frame: Baseline up to Week 52

  3. Number of target joints

    The target joint is a minimum of three bleeds into a single joint within a consecutive 6-month period.

    Time frame: Baseline up to Week 52

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — IPD will be shared with other researchers when ZS802 is fully approved.

Supporting information: Study protocol

Time frame: IPD will be shared with other researchers when ZS802 is fully approved.

Access criteria: IPD will be shared with other researchers when ZS802 is fully approved.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Oct 2025, 37 months after the start.

Of 72 non-industry interventional studies with no phase under Hemophilia A, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 38. This study's planned 37 months is above that.

Counting every sponsor, half of 75 studies reached it within 11 months; a quarter within 5 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2022
First posted
Aug 31, 2022
StartActual
Sep 29, 2022
Primary completionEst.
Oct 2025
CompletionEst.
Oct 2025
Last update
Feb 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05523128
Responsible party
Sponsor
First posted
Aug 31, 2022
Start date
Sep 29, 2022
Primary completion
Oct 2025 (estimated)
Completion
Oct 2025 (estimated)
Last update
Feb 21, 2025

Study contacts

Lei Zhang, MD
Contact
zhanglei1@ihcams.ac.cn
+86 022-23909240
Lei Zhang, MD
principal investigator · Institute of Hematology & Blood Diseases Hospital, China

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion